Status | Study |
RECRUITING |
Study Name: Fluorescence Guided Minimally-Invasive Resection Of Abdominal Paragangliomas Using Indocyanine Green Condition: Paraganglioma Date: 2023-11-16 Interventions: During minimally invasive surgery using intravenous administration of indocyanine green (ICG) near-infrared fluorescence imaging will be applied to id |
Recruiting |
Study Name: Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions Condition: Pheochromocytoma Paraganglioma Date: 2017-05-05 Interventions: Genetic: Genetic screening Germline and/or tumor samples will be screened for mutations |
Not yet recruiting |
Study Name: Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery Condition: Malignant Adrenal Gland Pheochromocytoma Malignant Paraganglioma Date: 2016-12-28 Interventions: Other: Laboratory Biomarker Analysis |
Available |
Study Name: Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma Condition: Pheochromocytoma Paraganglioma Date: 2016-11-08 Interventions: Drug: Ultratrace Iobenguane I131 Subjects will receive a dosimetry dose of AZEDRA and will undergo 3 who |
Recruiting |
Study Name: Cabozantinib for Malignant Pheochromocytoma Condition: Neuroendocrine Tumors Date: 2014-11-21 Interventions: Drug: Cabozantinib 60 mg by mo |
Recruiting |
Study Name: Evaluation of Gallium-68 DOTA-TOC Imaging of Somatostatin Receptor Positive Malignancies Condition: Neuroendocrine Tumor Paraganglioma Date: 2014-06-25 Interventions: Drug: DOTA-TOC PET/CT Single Gallium-68 DOTA-TOC PET/CT in patients with somatostatin receptor positive |
Active, not recruiting |
Study Name: Comparison of Diagnostic Performances of 68Ga-DOTATATE PET-CT and 18F-FDOPA PET-CT in Paragangliomas and Pheochromocytomas Evaluation Condition: Paragangliomas Pheochromocytomas Date: 2014-06-04 Interventions: Other: PET-CT |
Active, not recruiting |
Study Name: Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma Condition: Pheochromocytoma Paraganglioma Date: 2013-10-19 Interventions: Drug: Axitinib (AG-013736) Axitinib will be given as self-administered oral doses at the initial level o |
Withdrawn |
Study Name: Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma Condition: Phaeochromocytoma Paraganglioma Date: 2013-09-10 Interventions: Drug: Vandetanib 100 mg, 200 m |
Available |
Study Name: Expanded Access Protocol Using 131I-MIBG Therapy for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma Condition: Neuroblastoma Pheochromocytoma Parag Date: 2013-04-08 Interventions: Radiation: I-131 MIBG The therapeutic dose (5-18 mCi/kg at investigator's discretion; any dose ≥12 |